DDInter564 DDInter1819
Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera, and it was the third oral disease-modifying agent for multiple sclerosis approved by the FDA, following [fingolimod] and [teriflunomide]. Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis.
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Dimethyl fumarate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Dimethyl fumarate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Dimethyl fumarate {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Dimethyl fumarate {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Dimethyl fumarate may lead to a major life threatening interaction when taken with Tofacitinib
Dimethyl fumarate may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live